May 18, 2020 / 12:19 PM / in 9 days

BRIEF-Cellect Biotechnology's Apograft To Empower Cellular Treatment Of Covid-19 Related Pulmonary Diseases

May 18 (Reuters) - Cellect Biotechnology Ltd:

* CELLECT BIOTECHNOLOGY’S APOGRAFT™ TO EMPOWER CELLULAR TREATMENT OF COVID-19 RELATED PULMONARY DISEASES

* CELLECT BIOTECHNOLOGY - CLINICAL RESULTS IN GVHD STUDIES MAY BE BENEFICIAL IN COVID-19 AND CAR-T CYTOKINE STORM MANIFESTATIONS

* CELLECT BIOTECHNOLOGY - SIGNED A DEVELOPMENT AGREEMENT WITH CONSORTIUM TO EXAMINE THERAPEUTIC EFFECTS OF APOGRAFT TREATED STEM CELLS

* CELLECT BIOTECHNOLOGY LTD - DEVELOPMENT AGREEMENT INCLUDES A COMMERCIAL COMPONENT

* CELLECT BIOTECHNOLOGY LTD - DID NOT DISCLOSE TERMS OF AGREEMENT, NOR ANY MEMBERS OF INTERNATIONAL CONSORTIUM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below